Search the Newsreel

Abbott Laboratories Sales Rise on Diagnostics Growth

Abbott Laboratories reported higher revenue in the second quarter, primarily driven by increased sales in its diagnostics business. Despite the revenue boost, the company's profit for the quarter fell to $928 million from $1.78 billion in the prior year. Abbott also raised its full-year …

What Investors Don’t Understand About Abbott Laboratories

Abbott Laboratories (ABT) is undervalued by investors who still perceive it as a slow-growth bond proxy, despite significant transformations. The company's medical devices segment, particularly the FreeStyle Libre, is driving strong growth, and a recent $21 billion acquisition of Exact Sciences is set to …

Abbott eleva su previsión de beneficio por acción para 2026

Abbott Boosts 2026 Profit Guidance as Sales Across Business Rise

Abbott Laboratories has increased its 2026 profit guidance following a better-than-expected second quarter. The company now anticipates adjusted earnings per share to be between $5.45 and $5.60, representing a 5-cent improvement at the midpoint. This positive outlook is attributed to strong performance across most …

Reasons to Retain Abbott Stock in Your Portfolio for Now

Abbott Laboratories (ABT) is recommended as a stock to retain due to strong performance in its Nutrition business and growth in emerging markets within its Established Pharmaceuticals Division (EPD). However, potential headwinds include currency fluctuations, a dull macroeconomic environment, and increased operating costs. The …

Can Abbott (ABT) Turn Freenome Progress Into a Durable Diagnostics-Led Growth Story?

Abbott Laboratories is set to release its Q2 2026 results, with recent progress in diagnostics, particularly its collaboration with Freenome for blood-based colorectal cancer screening, as a key focus. This development could reshape Abbott's investment narrative towards diagnostics-led growth, helping to offset challenges in …

Abbott Laboratories (ABT) Stock Analysis: Potential 23.82% Upside Amid Strong Buy Ratings

Fabtech Technologies Targets ₹49–52 Cr North Africa Vet Facility, EU GMP Plant; Eyes FY27 Revenue of ₹500 Cr

Abbott Laboratories stock gains as Norges Bank acquires new institutional position

Abbott Laboratories (ABT) Stock Analysis: Tapping Into A 35.73% Potential Upside

Abbott Laboratories, Coca-Cola, and Walmart: Top Recession-Proof Stocks for 2026 - News and Statistics

Fabtech Technologies Cleanrooms Reports 46.93% Revenue Growth in FY26, Expands Into Solar, Data Centres, and Semiconductors

Why is Abbott Laboratories stock down today?

Fabtech Technologies Cleanrooms Limited Crosses Rs 200 Crore in Revenue, PAT Grows 18.95% in FY2026

Abbott stock tumbles below key moving averages as sellers dominate momentum: weekly outlook

Fabtech Technologies Reports 28.4% Revenue Growth in FY26 Amid Global Challenges

Fabtech Tech Standalone March 2026 Net Sales at Rs 110.20 crore, up 13.18% Y-o-Y

-3.05% for Abbott Laboratories stock as persistent selling outweighs support

Abbott Labs Q4 2025: Revenue Miss, Device Growth & Exact Sciences Acquisition - News and Statistics

Abbott Laboratories stock consolidates as bearish momentum continues after weak technical signals

Fabtech Tech Consolidated December 2025 Net Sales at Rs 62.76 crore, down 39.84% Y-o-Y

Abbott Laboratories (ABT) Stock: CEO Snaps Up $2M in Shares Despite Rough Quarter

Fabtech Technologies Completes ₹46.51 Crore Acquisition to Increase Kelvin Air Conditioning Stake to 60.53%

Fabtech Technologies Ltd. Share Price Today - Fabtech Technologies Ltd. Stock Price Live NSE/BSE

ABBOTT LABORATORIES PE Ratio (TTM): 35.56 — Near Median

Abitare In S.p.A.: dati finanziari previsioni stime e aspettative ABT | MarketScreener Italia